The abstract is read at the publisher; the summary is JClub's.
HER2-positive metastatic breast cancer has shifted from a median survival of <2 years to management for years, with long-term survival beyond 5 years becoming common.
- Why it matters: Treatment advances have changed recurrence patterns and the metastatic landscape, including more de novo metastatic presentations, creating new needs for sequencing and toxicity management.
- What they did: This review traces three decades of HER2-targeted therapy evolution, highlighting monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates, with emphasis on trastuzumab deruxtecan (T-DXd) moving earlier.
- The result: Earlier use of T-DXd across metastatic and curative-intent settings prompts questions about optimal sequencing and managing interstitial lung disease, with implications for subsequent HER2-directed options.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.